-
Morgan Stanley: Global Blood Therapeutics 'Clearly Encouraged' By Sickle Cell Therapy Data
Monday, December 11, 2017 - 11:12am | 508Global Blood Therapeutics Inc (NASDAQ: GBT), a clinical-stage biopharmaceutical company that focuses on treating blood-based disorders, released results from multiple data presentations during the 59th American Society of Hematology Annual Meeting & Exposition. The Analyst Morgan Stanley'...
-
Global Blood Shares Weak Into ASCAT; Concern With Timeline Of Sickle Cell Treatment May Be Weighing
Wednesday, October 5, 2016 - 2:28pm | 343Global Blood Therapeutics Inc (NASDAQ: GBT) shares are down 7.4 percent Wednesday on no official news from the company. However, a source familiar with the matter has told Benzinga that investors are concerned that the company’s 28-day efficacy timeline for GBT440 may need to be extended to...